Lorcan Nyhan

And then we are also less likely to reimburse them when it happens.

And ultimately, governments make choices.

And the advantages we're going to get

as a country and globally from AI and from the advances in tech, the only advantages we're going to see is in healthcare.

I think we know that.

AI isn't great, but there's going to be advances in healthcare.

So should we not be positioning ourselves to get the maximum advantage of those rather than being slow movers?

I take Gary's point on that once you get into the system, the idea is that once you're in there, it's relatively good.

But we are now falling behind when it comes to the access to drugs, particularly in the public system.

Dr. Michael McCarthy from UCG has been really strong on this, saying when patients come in to him now who have cancer, the first question he asks is, do you have private health insurance or public?

Because that massively now changes the access to the newest drugs that they're going to have because we are so slow and because of public reimbursement.

And then even within that, we then just don't approve elements of drugs.

So

It's no longer the saying that once you're in the system, you're definitely getting the best access to the drugs, which I do think we need to be very, very careful about.

And then even wider than that, look, we spend about 3 billion every year on drugs, which is a lot of money.

But like the VAT cut that the government approved, which is a choice, is worth about 700 million every year, the hospitality VAT cut from the last budget.

So like this is all about choices.

We're not here saying give everybody what they want all the time.

We know you need to make hard choices.

But wider than this, the government can make a choice on drugs that says, do you know what?